Trial reportThe Prostate2015
Prospective study of DNA methylation at LINE-1 and Alu in peripheral blood and the risk of prostate cancer.
Trial report in The Prostate, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- The Years 2015-2025 as a Prospective Decade for the Identification of Specific Methylation Biomarkers of Prostate Cancer.Biomolecules · 2025Review
- Exposure to smoky coal combustion emissions and leukocyte Alu retroelement copy number.Carcinogenesis · 2023Article
- Elevated Alu retroelement copy number among workers exposed to diesel engine exhaust.Occupational and environmental medicine · 2021Article
- Discovery of novel DNA methylation biomarkers for non-invasive sporadic breast cancer detection in the Latino population.Molecular oncology · 2021Article
- Article
- A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility.BMC cancer · 2020Article
- Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.Diagnostic pathology · 2018Article
- Ginsenoside Rh2 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of MCF-7 breast cancer cells.Journal of ginseng research · 2018Article
- Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer ScreeningIranian biomedical journal · 2018Article
- LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients.Oncotarget · 2017Article
- A pilot study assessing the association between paraoxonase 1 gene polymorphism and prostate cancer.Turkish journal of urology · 2017Article
- Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients.Carcinogenesis · 2017Article
- Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk.British journal of cancer · 2017Article
- World Trade Center (WTC) dust exposure in mice is associated with inflammation, oxidative stress and epigenetic changes in the lung.Experimental and molecular pathology · 2017Article
- What's in a name? Context-dependent significance of 'global' methylation measures in human health and disease.Clinical epigenetics · 2017Article
- Deciphering the role of DNA methylation in multiple sclerosis: emerging issues.Auto- immunity highlights · 2016Article
- Prospective changes in global DNA methylation and cancer incidence and mortality.British journal of cancer · 2016Article
- Correlation between the germline methylation status in ERβ promoter and the risk in prostate cancer: a prospective study.Familial cancer · 2016Article
- Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- When Prostate Cancer Circulates in the Bloodstream.Diagnostics (Basel, Switzerland) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundEvidence suggests that global blood DNA methylation levels may be associated with the risk of various cancers, but no studies have evaluated this relationship for prostate cancer.
methodsWe used pyrosequencing to quantify DNA methylation levels at the long interspersed nuclear element 1 (LINE-1) and Alu repetitive elements in pre-diagnostic blood samples from 694 prostate cancer cases and 703 controls from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. We evaluated prostate cancer risk associated with the mean methylation level for each element using logistic regression, adjusting for potential confounders.
resultsWe did not observe a significant association with prostate cancer for LINE-1 [odds ratio (OR) for the highest compared to the lowest quartile = 1.01, 95% confidence interval (CI): 0.73-1.39, Ptrend = 0.99] or Alu (OR = 0.94, 95% CI: 0.68-1.29, Ptrend = 0.69) methylation levels overall. However, for Alu, we observed that higher DNA methylation levels were associated with a significant increased risk for those diagnosed 4 or more years after blood draw (OR = 2.26, 95% CI: 1.27-4.00, Ptrend = 4.4 × 10(-3) ). In contrast, there was no association for those diagnosed 2 (OR = 1.13, 95% CI: 0.67-1.90, Ptrend = 0.64) or 3 years after draw (OR = 1.22, 95% CI: 0.71-2.07, Ptrend = 0.32), and a decreased risk for those diagnosed less than 2 years after draw (OR = 0.40, 95% CI: 0.25-0.65, Ptrend = 3.8 × 10(-5) ; Pheterogeneity = 5.3 × 10(-6) ).
conclusionsAlthough LINE-1 DNA methylation levels were not associated with prostate cancer, we observed an association for Alu that varied by time from blood draw to diagnosis. Our study suggests that elevated Alu blood DNA methylation levels several years before diagnosis may be associated with an increased prostate cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.